Ongoing Clinical Trials for Papillary Serous Endometrial Carcinoma
There is currently 1 ongoing clinical trial for papillary serous endometrial carcinoma, also known as uterine serous carcinoma. This trial is testing a new medication called azenosertib (ZN-c3) for women whose cancer has come back or has not responded to previous treatments. The study is being conducted in three European countries: France, Italy, and Spain.
Clinical trial locations
- France
- Italy
- Spain
Study of Azenosertib (ZN-c3) for Women with Recurrent or Persistent Uterine Serous Carcinoma
This trial is designed for women with uterine serous carcinoma that has either returned after treatment or has continued despite treatment. Uterine serous carcinoma is an aggressive form of cancer that originates in the lining of the uterus and is known for spreading quickly. This study is evaluating a new oral medication called azenosertib, also known by its research code ZN-c3.
Who can participate:
To join this trial, you must be a woman aged 18 or older with confirmed recurrent or persistent uterine serous carcinoma. Your cancer must be measurable by scans or physical examination. You should have already tried standard treatments, including platinum-based chemotherapy and a PD-(L)1 inhibitor, unless these treatments were not suitable for you or are not available in your area. If your tumor is HER2-positive, you should have also received at least one HER2-targeted therapy unless you were not eligible for it or it was unavailable.
Your general health must be good enough to participate, meaning you should be able to carry out normal activities or at least light work. This is measured by an ECOG Performance Status score of 0 or 1. Your blood tests must show adequate function of your bone marrow, liver, and kidneys. For example, your white blood cell count, hemoglobin levels, and platelet count must be within acceptable ranges. Your liver enzymes and kidney function must also meet specific criteria.
You will need to provide a tissue sample from your tumor that was collected within the past three years. If you are of childbearing age, you must agree to use effective contraception during the study and for six months after receiving the last dose of the study medication.
Who cannot participate:
This study is only for women with recurrent or persistent uterine serous carcinoma. Men cannot participate. If your cancer is a carcinosarcoma, you are not eligible. Additionally, individuals who are considered part of a vulnerable population requiring special protection cannot join the study.
What the trial involves:
The main focus of this trial is to test the safety and effectiveness of azenosertib. At the molecular level, this medication works by blocking certain enzymes that cancer cells need to grow and divide. By doing this, it may slow down or stop the cancer from spreading further.
The study follows a structured approach. After you join, you will begin taking azenosertib orally in capsule form. Throughout the trial, you will have regular check-ups to monitor how your body responds to the medication and to check for any side effects. Blood tests and other laboratory assessments will be performed regularly to ensure your safety.
The effectiveness of the treatment will be measured by tracking changes in the size of your tumor using standardized criteria called RECIST v1.1. The doctors will look for signs that the tumor is shrinking or has stopped growing. If the treatment is working well and you are tolerating it without serious side effects, you will continue taking the medication as planned.
The study is expected to conclude by May 31, 2025, at which point all the collected information will be analyzed to determine whether azenosertib could be a beneficial treatment option for women with this type of cancer.
Summary
Currently, there is one active clinical trial available for women with papillary serous endometrial carcinoma. This trial is testing azenosertib (ZN-c3), a targeted therapy designed to inhibit cancer cell growth. The study is being conducted across three European countries: France, Italy, and Spain, providing access to women in these regions who have limited treatment options after their cancer has returned or persisted despite standard therapies.
The trial specifically targets patients who have already undergone platinum-based chemotherapy and immunotherapy, reflecting the need for new treatment options for advanced or difficult-to-treat cases. The study’s focus on safety and tumor response will help determine whether this new medication could offer hope to women facing this aggressive form of cancer.
